[Progress of therapy in patients with multiple sclerosis]

MMW Fortschr Med. 2010 Mar 4;152(9):42-4.
[Article in German]
No abstract available

MeSH terms

  • 4-Aminopyridine / administration & dosage
  • 4-Aminopyridine / adverse effects
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / adverse effects
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Brain / pathology
  • Cladribine / administration & dosage
  • Cladribine / adverse effects
  • Clinical Trials as Topic
  • Fingolimod Hydrochloride
  • Magnetic Resonance Imaging
  • Multiple Sclerosis, Chronic Progressive / diagnosis
  • Multiple Sclerosis, Chronic Progressive / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab
  • Propylene Glycols / administration & dosage
  • Propylene Glycols / adverse effects
  • Rituximab
  • Sphingosine / administration & dosage
  • Sphingosine / adverse effects
  • Sphingosine / analogs & derivatives

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Natalizumab
  • Propylene Glycols
  • Cladribine
  • Rituximab
  • 4-Aminopyridine
  • Fingolimod Hydrochloride
  • Sphingosine